Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco

An open-label pharmacokinetic (PK) study was conducted to identify possible interactions between buprenorphine/naloxone and raltegravir. Twelve HIV-uninfected volunteers who had been on at least 3 weeks of stable treatment with buprenorphine/naloxone were given raltegravir 400 mg BID. They underwent intensive PK sampling at steady state before and after the addition of raltegravir. Compared with baseline values, there was no significant change in C_max or AUC of buprenorphine, its primary metabolite norbuprenorphine, or naloxone, and subjects did not experience opioid withdrawal symptoms. Raltegravir C_max and AUC levels were not significantly different from those of historic controls. Patients on buprenorphine/naloxone may safely receive raltegravir with no dosage adjustments.

References

1. Bruce RD, Moody K, Chodkowski D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir. In: Program and abstracts of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 17-20, 2011; Rome. Abstract MOPE176.